OPC 108459

Drug Profile

OPC 108459

Alternative Names: OPC-108459

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical Development & Commercialization
  • Class Antiarrhythmics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atrial fibrillation

Most Recent Events

  • 13 Sep 2016 Discontinued - Phase-I for Atrial fibrillation in USA, Japan, United Kingdom, Spain, Netherlands, Denmark, Germany, Italy (IV) before September 2016 because of insufficient data in phase I trial (Otsuka Pharmaceuticals pipeline, September 2016)
  • 23 Sep 2014 Phase-I clinical trials in Atrial fibrillation in United Kingdom, Italy, Germany, Netherlands and Spain (IV)
  • 27 Feb 2014 Phase I development is ongoing in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top